~~<i id='F0CBBF9E3D'><strike id='F0CBBF9E3D'><tt id='F0CBBF9E3D'><pre id='F0CBBF9E3D'></pre></tt></strike></i>~~

Home» explore» focus

focus

author：Wikipedia 2025-10-02 07:52:10 Page View：79651

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： People can get long Covid without testing positive for virus: Study
Next article： Virginia high school admissions case could be legal follow

comprehensive

Trump demands the U.S. pay no more for drugs than other countries … again

EthanMiller/GettyImagesWASHINGTON—FormerPresidentTrumpisbacktocampaigningfortyingMedicaredrugpricest

People can get long Covid without testing positive for virus: Study

MahmoudIllean/APOfthe103millionconfirmedcasesofCovid-19intheU.S.,anestimatedone-thirdhaveledtolongCo

After affirmative action ruling, medical educators look to 'holistic review'

AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

FDA advisory panel to debate high blood pressure devices

APStockAnadvisorycommitteetotheFoodandDrugAdministrationwillconveneonTuesdaytoevaluatethebenefitsofr